Simplifying Global Compliance
Final Pivotal Trial Guidance Addresses Unblinded Device Studies
The FDA strongly recommends blinding in device pivotal trials, when possible, and notes that, even if the subject and/or the investigator cannot be blinded, devicemakers may be able to secure a blinded third-party evaluator to assess the study endpoints.
To View This Article:
Buy This Article Now
Copyright ©2017. All Rights Reserved.
Design, CMS, Hosting & Web Development :: ePublishing